547 related articles for article (PubMed ID: 23618815)
1. History of gene therapy.
Wirth T; Parker N; Ylä-Herttuala S
Gene; 2013 Aug; 525(2):162-9. PubMed ID: 23618815
[TBL] [Abstract][Full Text] [Related]
2. Wacław Szybalski's contribution to immunotherapy: HGPRT mutation & HAT selection as first steps to gene therapy and hybrid techniques in mammalian cells.
Bigda JJ; Koszałka P
Gene; 2013 Aug; 525(2):158-61. PubMed ID: 23562724
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy on demand: site specific regulation of gene therapy.
Jazwa A; Florczyk U; Jozkowicz A; Dulak J
Gene; 2013 Aug; 525(2):229-38. PubMed ID: 23566848
[TBL] [Abstract][Full Text] [Related]
4. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
Li PX; Ngo D; Brade AM; Klamut HJ
Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
[TBL] [Abstract][Full Text] [Related]
5. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
6. Human gene therapy: a brief overview of the genetic revolution.
Misra S
J Assoc Physicians India; 2013 Feb; 61(2):127-33. PubMed ID: 24471251
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene.
Yang L; Hwang R; Chiang Y; Gordon EM; Anderson WF; Parekh D
Clin Cancer Res; 1998 Mar; 4(3):731-41. PubMed ID: 9533543
[TBL] [Abstract][Full Text] [Related]
8. The 50th anniversary of gene therapy: beginnings and present realities.
Szybalski W
Gene; 2013 Aug; 525(2):151-4. PubMed ID: 23500596
[TBL] [Abstract][Full Text] [Related]
9. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors.
Hasegawa Y; Emi N; Shimokata K; Abe A; Kawabe T; Hasegawa T; Kirioka T; Saito H
Am J Respir Cell Mol Biol; 1993 Jun; 8(6):655-61. PubMed ID: 8391827
[TBL] [Abstract][Full Text] [Related]
10. Resistance developing after long-term ganciclovir prodrug treatment in a preclinical model of NSCLC.
Kurdow R; Schniewind B; Boehle AS; Haye S; Boenicke L; Dohrmann P; Kalthoff H
Anticancer Res; 2004; 24(2B):827-31. PubMed ID: 15161034
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated suicide gene therapy for experimental bladder cancer.
Sutton MA; Berkman SA; Chen SH; Block A; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Woo SL; Lerner SP
Urology; 1997 Feb; 49(2):173-80. PubMed ID: 9037277
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene.
Ural AU; Takebe N; Adhikari D; Ercikan-Abali E; Banerjee D; Barakat R; Bertino JR
Gynecol Oncol; 2000 Mar; 76(3):305-10. PubMed ID: 10684701
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
14. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
[TBL] [Abstract][Full Text] [Related]
15. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
[TBL] [Abstract][Full Text] [Related]
16. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy.
Loimas S; Toppinen MR; Visakorpi T; Jänne J; Wahlfors J
Cancer Gene Ther; 2001 Feb; 8(2):137-44. PubMed ID: 11263529
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
19. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.
Kong B; Wang W; Liu C; Song L; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Wang B; Wei MQ; Yang Q
In Vivo; 2003; 17(2):153-6. PubMed ID: 12792977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
